Online inquiry

IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ825MR)

This product GTTS-WQ825MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets LRRC15 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001135057.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 131578
UniProt ID Q8TF66
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ825MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11036MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MCLA-128
GTTS-WQ15143MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SYNT-001
GTTS-WQ756MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AB0024
GTTS-WQ4707MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-986168
GTTS-WQ15253MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ14474MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA RO-7105705
GTTS-WQ153MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ10769MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA M-70
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW